Research Updates

Neuroprotection represents a promising frontier in the treatment of glaucoma, offering hope and new avenues for preserving your sight.

The future of glaucoma research holds immense promise. With each discovery we move closer to achieving more effective treatments and, ultimately, a cure for glaucoma.

The Catalyst for a Cure research teams are generating insights and results as they seek new treatments and cures for glaucoma and other neurodegenerative diseases.

A new study explored whether mitochondrial function is associated with the rate at which glaucoma patients lose vision.

Two Concurrent Catalyst Initiatives Push for a Glaucoma Cure — and More

Glaucoma Research Foundation is dedicated to scientific research that deepens our understanding of glaucoma, generates new treatments, and will ultimately lead to a cure.

Glaucoma and Alzheimer’s Disease are two of the most severe age-related conditions affecting millions worldwide.

The Catalyst for a Cure Vision Restoration Initiative (CFC3) is seeking innovative ways to regrow or replace retinal ganglion cells and axons, which make up the optic nerve.

The Melza M. and Frank Theodore Barr Foundation Catalyst for a Cure Initiative to Prevent and Cure Neurodegeneration began their investigations in 2022.

Currently, there is extensive research and development on “drop-free” or “drop-less” technologies for delivering glaucoma medications to the eye.

The Catalyst for a Cure Vision Restoration team has identified a set of three genes that, when inhibited, improve the survival of optic nerve cells in models of glaucoma.

Smart contact lenses use tiny sensors to collect data about the pressure inside your eye. They can measure and monitor changes in IOP, or provide on-demand release of glaucoma medication.

“Neuroprotection: A New Path for Glaucoma Patients” was the topic of the 2022 Weston Family Lecture presented virtually on October 27, 2022.

What is neurodegeneration? And how will discoveries related to it affect people with glaucoma?

The Catalyst for a Cure Initiative to Prevent and Cure Neurodegeneration.

Made possible by visionary donors, Glaucoma Research Foundation’s latest research initiative targets the shared roots of conditions that occur when neurons deteriorate and die.

Dr. John G. Flanagan discusses recent discoveries that could cure glaucoma based on key research accomplishments from 20 years of Catalyst for a Cure.

Research paper summarizes the most important common elements that characterize progression in neurodegeneration and hope for new therapies to help patients with these devastating diseases.

This article summarizes published findings from Catalyst for a Cure (CFC1) research scientists and subsequent discoveries by Dr. Rebecca Sappington’s lab at Vanderbilt and Wake Forest.

Since 1980, the American Academy of Ophthalmology has presented a named lecture in honor of pioneering glaucoma specialist Robert N. Shaffer, MD in conjunction with their annual meeting.

Pilot project grants support new and promising ideas in the field of glaucoma research.

When Glaucoma Research Foundation first launched Catalyst for a Cure in 2002, our bold idea was to recruit the most promising young researchers from different fields to work collaboratively.

Xin Duan, PhD is an Associate Professor of Ophthalmology at the UC San Francisco Weill Institute of Neuroscience, where in 2017 he received a Trailblazer Award in Neuroscience.

In this interview, we learn about Padhu’s extensive background, his research interests, and his personal passions.

Sayoko “Sy” Moroi is the Jerome Jacobson Professor of Ophthalmology and Visual Sciences at University of Michigan, Kellogg Eye Center.